Xellia Pharmaceuticals Strengthens Commitment To Innovation In Anti-Infectives With New API R&D Center Of Excellence In Oslo

State-of-the-art facility will focus on expanding API development and discovery of novel antibiotics

Copenhagen, Denmark – 18 November 2014 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced the opening of a new active pharmaceutical ingredients (API) R&D Center of Excellence in Oslo, Norway. Xellia specializes in the manufacture of quality, fermented and difficult-to-manufacture APIs. The Company is also developing APIs based on chemical synthesis, which involves complex, strictly controlled chemical reactions, utilizing its innovative Route-of-Synthesis procedures.

The new 1,900m2 state-of-the-art facility replaces the R&D center at the former manufacturing site in Oslo. Xellia’s 50 specialist API researchers are focusing on developing new APIs and on the identification of improvements in microbial strain development as well as fermentation and purification processes to increase the yield and efficiencies in the upstream and downstream manufacturing process. This work supports the development of new treatments, and the manufacture and continuity of supply of existing treatments for serious and life threatening diseases to better serve Xellia’s over 500 pharmaceutical customers in more than 70 countries.

The research team is also working in partnership with scientists at SINTEF Materials and Chemistry (Trondheim, Norway) and the Statens Serum Institute (Copenhagen, Denmark). The scientists are collaborating in research into resistant bacteria with the goal to improve and revive the use of existing important last-line anti-infective treatments. Developing safer antibiotics will extend their utility making them more suitable for intended therapeutic administration. In addition, Xellia is working with these partners to discover new lead compunds that will target multi-drug resistant Gram-negative bacteria which cause severe and hard to treat diseases. These programs are supported by the Research Council of Norway (NFR).

Carl-Åke Carlsson, CEO, Xellia said: “R&D is a key priority for Xellia and is an integral part of our continued global strategy of investing for growth. We have a highly skilled team of API experts in Oslo and we are committed to expanding and improving our API products which combat serious bacterial and fungal infections, including antibiotic resistant varieties. “The global crisis of antibiotic resistance is one of the most serious threats to health and an area where urgent action is needed. The European Antibiotic Awareness Day highlights the part that everyone must play to help tackle this. Xellia’s anti-infective portfolio is also becoming increasingly important for global health as a result of the need to control rising healthcare costs in developed countries, and the inability of patients in developing countries to afford life-saving medicines.”

The new API R&D Center of Excellence is part of the latest phase of Xellia’s on-going expansion plans which included the investment in the Company’s Finished Dosage Form R&D Center of Excellence in Zagreb, Croatia in May and the acquisition of Fresenius Kabi’s US manufacturing plant in Raleigh, NC, USA in July.

- ENDS -

About Xellia

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,000 people.

Xellia is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway. Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.

Further information about Xellia can be found at: www.xellia.com.

Issued for and on behalf of Xellia by Instinctif Partners.

For more information please contact:

Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00
Dr Aleksandar Danilovski, Vice President Global R&D
Tel: +45 23 21 90 50 / +385 98 321 346
Instinctif Partners (media relations)
Melanie Toyne Sewell / Eileen Paul / Jen Lewis
Tel: +44 (0) 20 7457 2029 / +44 (0)1260 296 500
Email: xellia@instinctif.com

Help employers find you! Check out all the jobs and post your resume.

Back to news